Home › Funds › Soleus Capital Management, L.P. › CCCC

Soleus Capital Management, L.P. position in CCCC

C4 THERAPEUTICS INC · Health Care

Soleus Capital Management, L.P. reported holding 3,377,981 shares of CCCC (C4 THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$15.8M, representing 0.54% of its reported portfolio and ranking #47 among its reported holdings. Soleus Capital Management, L.P. has disclosed CCCC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.38M sh
Reported value held$15.78M
Portfolio Weight0.54%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s CCCC position evolved

Soleus Capital Management, L.P. first disclosed a stake in CCCC in Q3 2023 at 2,692,020 shares (US$5.0M). The position peaked in Q3 2024 at 6,603,996 shares, worth US$37.6M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 3,377,981 shares valued at US$15.8M — a reduction of -425,961 shares quarter over quarter.. Notable position changes include a 65% increase in Q2 2024 (shares rose 23% over the following quarter), a 63% increase in Q3 2024 (shares fell 37% over the following quarter), a 46% trim in Q4 2025 (shares rose 38% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.69M $5.01M New
Q4 2023 1.84M $10.37M Reduce
Q1 2024 2.46M $20.09M Add
Q2 2024 4.05M $18.72M Add
Q3 2024 6.60M $37.64M Add
Q4 2024 6.98M $25.12M Add
Q1 2025 6.98M $11.17M Hold
Q2 2025 6.98M $9.98M Hold
Q3 2025 7.05M $15.66M Add
Q4 2025 3.80M $7.27M Reduce
Q1 2026 3.80M $10.00M Hold
Q2 2026 3.38M $15.78M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CCCC and 13F data

CCCC (C4 THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$33.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CCCC

All CCCC fund holders →

FAQ

How long has Soleus Capital Management, L.P. held CCCC?

Soleus Capital Management, L.P. has disclosed CCCC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in CCCC?

As of Q2 2026, Soleus Capital Management, L.P. holds 3.38M shares of CCCC (C4 THERAPEUTICS INC), valued at $15.78M, representing 0.54% of its reported portfolio and ranking #47.

Has Soleus Capital Management, L.P. been buying or selling CCCC?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in CCCC. The position peaked in Q3 2024 at 6.60M shares.

Which other funds hold CCCC?

Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.